Anavex Life Sciences Corp is a New York-based company dedicated to developing innovative small molecule treatments for a range of central nervous system (CNS) diseases, including Alzheimer's, Parkinson's, Rett syndrome, and other rare conditions. Through their proprietary SIGMACEPTOR discovery platform, they aim to target the upstream Sigma-1 receptor (SIGMAR1) to unlock the body's own defenses and potentially reverse CNS conditions. With a focus on person-centered dedication, Anavex's therapeutic candidates, produced by their portfolio platform, offer novel modes of action for various CNS disorders. Their research suggests that the activation of SIGMAR1 can restore complete housekeeping function within the body, playing a pivotal role in neural cell homeostasis and neuroplasticity. As they progress from research to a commercial stage, Anavex aims to bring their treatments to market, benefiting patients worldwide and revolutionizing the treatment paradigm for CNS diseases.Generated from the website

Vornado Realty Trust

Bally Technologies Inc

Wildenstein & Co Inc

Aks Salon